Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer by Robert Bazell

Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. This is a very detailed look at the development of a new kind of treatment for breast cancer. I have a family member affected, and I am a physician, so it is good to know as much as possible, though I do not treat breast cancer as a primary care physician. The lives saved and sadly those lost.

Bazell paints a complete picture of the development of the nontoxic "miracle" drug known as Herceptin, which purportedly halts and reverses the "overexpressed Her-2 protein" affecting 30% of breast cancer patients, shrinking and even eliminating spreading tumors  . 4 more to go!!! I had 4 rounds of AC then 12 rounds of Taxol and Herceptin with 3 rounds of a cousin to Herceptin which I think was prujeta?.

Her-2: The Making of Herc. has been added to your Cart. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Terrific book about discovery of Her-2 and Herceptin. Although published in 1998, it gives the back story of these discoveries and the journey to FDA approval. Very informative and inspirational. One person found this helpful.

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Five years later she remains cancer-free.

Что Говорит Цвет Менструальной Крови о Вашем Здоровье - Продолжительность: 8:16 AdMe.

Her-2 is the biography of Herceptin, the drug that offers promise for hundreds of thousands of breast cancer patients. In his book, Robert Bazell presents how Herceptin was born in the middle of dramatic discoveries, scientific investigations, money from Hollywood, politics, strong egos, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient’s bedside. time they had left on an unproven treatment

Her-2 is the biography of Herceptin, the drug. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu-a protein that makes cancer cells grow especially quickly- produced by a gene found in 25 to 30 percent of all breast tumors

Additional Two years later she underwent a mastectomy & chemotherapy, breast cancer aggressive Barbara Bradfield had returned & spread his lungs. The outlook is bleak. Five years later she remains free of cancer. Her-2 is the biography of Herceptin, a drug that dramatic reactions Barbara Bradfield & other women has caused, the tests & features the promise of hundreds of thousands of patients with breast cancer. In contrast into chemotherapy or radiation, Herceptin is never clear side effects.

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer reads like a novel at first. Oncologist Dennis Slamon has spent 13 years "obsessed with a molecule called Her-2," which he believed "held the key to nothing less than curing breast cancer. He keeps bringing the reader back to the threads of the personal stories we are the women with breast cancer and their determination to recapture their health. This is what makes Her-2 so compelling.

In the introduction to this narrative about the making of the new breast cancer drug Herceptin, geneticist Mary-Claire King observes that "good science makes a great yarn. That sums up the appeal of Robert Bazell's new book. Bazell, chief science correspondent for NBC News, proves himself a diligent reporter and entertaining writer in detailing the story of Herceptin. He gives us an inside look at the egos, politics, economics and emotions that play a major role in science and biotechnology.